ARTICE
Phase 2Biologic
ARTICE is one of 46 biologic programs targeting Septic Shock. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Septic Shock
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glypressin
MMallinckrodt
Approved
Pitressin
AAultman Health Foundation
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Zocor
OOrganon and Co
Approved
Florinef
Jazz PharmaceuticalsPhase 3
Cyklokapron
JJ Molner
Approved
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARTICE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- AArtcline GmbH